RNS Number : 1392T MaxCyte, Inc. 16 March 2023 MaxCyte announces filing of Form 10-K for the full year period ended December 31, 2022 ROCKVILLE, MD , March 16, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 1351T MaxCyte, Inc. 16 March 2023 MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results 31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue ROCKVILLE, MD , March 16, 2023 -
RNS Number : 3036S MaxCyte, Inc. 08 March 2023 MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology MaxCyte's Scientific Advisory Board will provide guidance to shape the technical direction of the company's
RNS Number : 0738S MaxCyte, Inc. 07 March 2023 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance · Full year 2022 total revenue expected to be approximately $44.3 million , representing growth of 31% over full year
RNS Number : 0685P MaxCyte, Inc. 06 February 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights ROCKVILLE, MD , February 6, 2023 - MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on
RNS Number : 7153O MaxCyte, Inc. 02 February 2023 MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences ROCKVILLE, MD , February 2, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering
RNS Number : 2143O MaxCyte, Inc. 30 January 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights ROCKVILLE, MD , January 30, 2023 - MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on
RNS Number : 5691L MaxCyte, Inc. 04 January 2023 MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs MaxCyte's Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell
RNS Number : 5209I MaxCyte, Inc. 05 December 2022 MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases Curamys to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to help advance its cell
RNS Number : 5048I MaxCyte, Inc. 02 December 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 2 December 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to
